Lantheus Holding Stock Price, News & Analysis

Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, CEO, and Bob Marshall, CFO, will present at the Jefferies Healthcare Conference on June 9 at 11:00 a.m. ET. The event will take place in New York City, showcasing the company's commitment to innovative imaging diagnostics and therapeutics. Investors can access a live webcast of the presentation on the company’s website, with a replay available for 30 days post-event. Lantheus is a leader in advanced medical imaging solutions, aiming to enhance patient care through its diverse product portfolio.

Lantheus Holdings, Inc. (NASDAQ: LNTH) announced key presentations at the 2022 SNMMI Meeting in Vancouver, scheduled for June 11-14, 2022. The event will feature oral presentations on two significant imaging agents: PYLARIFY® (piflufolastat F18) for prostate cancer and PYLARIFY AI™, an AI platform for PSMA PET imaging. PYLARIFY's efficacy will be discussed concerning androgen deprivation therapies, while PYLARIFY AI™ will highlight a Phase III study aimed at rapid lesion detection. These advancements reflect Lantheus's commitment to innovative diagnostics and therapeutics in oncology.

Lantheus Holdings has announced its Inaugural Investor Day, scheduled for May 17, 2022, where it will outline its long-term growth strategy and financial targets. The event will feature updates from the management team on key commercial products and development assets. CEO Mary Anne Heino expressed enthusiasm for providing insights into their business and growth strategies aimed at delivering long-term value for patients and shareholders. The live webcast will be accessible for replay post-event.

Lantheus Holdings (NASDAQ: LNTH) released findings from a retrospective study analyzing the use of its PYLARIFY® AI in monitoring treatment response in prostate cancer patients. The study demonstrated that changes in PSMA scan indices correlated significantly with prostate-specific antigen (PSA) responses post-androgen deprivation therapy. Patients exhibited a 97% average decline in PSA levels, paired with significant reductions in PSMA indices in lymph nodes and bone. These results suggest PYLARIFY AI may enhance the quantification of disease burden and response to therapy in prostate cancer management.

Lantheus Holdings announced the initiation of a Phase 2 trial for NM-01, a technetium-99m SPECT imaging agent aimed at assessing PD-L1 expression in non-small cell lung cancer (NSCLC). The PELICAN trial will evaluate NM-01's ability to identify responders to checkpoint inhibitor therapies compared to traditional immunohistochemistry methods. Conducted in partnership with NanoMab Technology at King’s College London, this trial seeks to improve patient selection for treatment and offers a non-invasive alternative to biopsies. The outcome could enhance treatment efficacy and minimize unnecessary side effects.

Lantheus Holdings has announced updates from the National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) regarding the use of PYLARIFY® (piflufolastat F 18) for prostate cancer. The guidelines now include PYLARIFY as a recommended agent for patient selection in PSMA-targeted radioligand therapy. This follows PYLARIFY's FDA approval and aims to enhance access to targeted treatments for patients with advanced prostate cancer.

NORTH BILLERICA, Mass., May 10, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that President and CEO Mary Anne Heino, along with CFO Bob Marshall, will present at the UBS Global Healthcare Conference. The presentation is scheduled for 8:30 a.m. ET on May 24, 2022, in New York. Investors can access a live webcast through the Company’s website, with a replay available for 30 days post-event. Lantheus is known for its innovative imaging diagnostics and AI solutions aimed at serious medical conditions.

Lantheus Holdings reported a remarkable first quarter of 2022 with worldwide revenue of $208.9 million, a 125.8% increase from the previous year. The company's GAAP net income surged to $43.0 million or $0.61 per share, up from $9.0 million or $0.13 per share in Q1 2021. Adjusted fully diluted EPS rose to $0.97, significantly higher than $0.05 a year prior. The company also provided a Q2 revenue guidance of $200 million - $215 million and updated its full-year revenue guidance to $800 million - $835 million.

Lantheus Holdings (NASDAQ: LNTH) will host a conference call on April 29, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial and operating results. Investors can access the call via telephone or through a live webcast on the company's investor website. A replay will be available two hours post-call for 30 days. Lantheus, based in North Billerica, Massachusetts, specializes in imaging diagnostics and therapeutics, with a diverse product portfolio including DEFINITY®, PYLARIFY®, and RELISTOR®.